Industry

Not for distribution to U.S. news wire services or for dissemination in the U.S. TORONTO–(BUSINESS WIRE)–LifeWorks Inc. (the “Company” or “LifeWorks”) (TSX: LWRK) today reported its financial results for the three and six-month period ended June 30, 2022 (all amounts are in Canadian dollars, unless noted otherwise). LifeWorks acquisition by TELUS Binding agreement for C$2.9 … [Read more…]

Not for distribution to U.S. news wire services or for dissemination in the U.S. VANCOUVER, British Columbia & TORONTO–(BUSINESS WIRE)–TELUS Corporation (“TELUS”) (TSX: T; NYSE: TU) and LifeWorks Inc. (“LifeWorks”) (TSX: LWRK) today announced that the Ontario Superior Court of Justice (Commercial List) has granted its final order (the “Court Approval”) approving the plan of … [Read more…]

MELVILLE, N.Y.–(BUSINESS WIRE)–Henry Schein, Inc. (Nasdaq: HSIC) announced the passing today of E. Dianne Rekow, DDS, Ph.D., a member of the Company’s Board of Directors since 2014 and a leader in the development of digital dentistry. “Dianne was an extraordinary board member and an internationally known authority on aesthetic and restorative dentistry as well as … [Read more…]

Evaluation of PALISADE-1 continues and interim analysis of PALISADE-2 begins Preliminary data from nearly 200 subjects in the PALISADE open label safety study suggest that continued as-needed use of PH94B has potential to achieve cumulative functional improvement in the severity of social anxiety disorder (SAD) SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–$VTGN #mentalhealth—VistaGen Therapeutics, Inc. (Nasdaq: VTGN), … [Read more…]

Corporate restructuring underway and MASTERS-2 clinical trial prioritized Conference call begins at 4:30 p.m. Eastern time today CLEVELAND–(BUSINESS WIRE)–$ATHX #ARDS–Athersys, Inc. (NASDAQ: ATHX) announced today its financial results for the three and six months ended June 30, 2022 and provided a business update. Second quarter 2022 Corporate and Operational Highlights: Corporate Restructuring Implemented a restructuring … [Read more…]

On Track to Dose the First Patient in the Phase 1 Study Evaluating Belzupacap Sarotalocan (AU‑011) for the Treatment of Non-Muscle Invasive Bladder Cancer in Q3 2022 On Track to Initiate Pivotal Trial in Early-Stage Choroidal Melanoma in Q4 2022 BOSTON–(BUSINESS WIRE)–Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of … [Read more…]

Signs Supply Agreement and Receives First Commercial Purchase Order from Top-Tier Medtech Company for Bioptx™ Baseline Band, Targets Fourth Quarter to Begin Shipping Signs First Contract Research Organization Partnership to Develop and Evaluate Rockley’s Bioptx™ Biomarker Sensing Platform for Use in Clinical Trials Bolsters Board of Directors and Establishes Scientific Advisory Board OXFORD, England & … [Read more…]

— Full data support the potential of obicetrapib to address unmet medical need for millions of patients who cannot achieve their LDL-C targets with high-intensity statin therapy (HIS) alone — — Treatment with obicetrapib in patients on high-intensity statin therapy was observed to have statistically significant impact on LDL-C, as well as significant impacts on … [Read more…]

˗ ALBRIOZA™ (also known as AMX0035) now commercially available in Canada, representing first product launch for Amylyx ˗ FDA Advisory Committee meeting to review new drug application for AMX0035 for the treatment of ALS scheduled for September 7, 2022; assigned PDUFA action date of September 29, 2022; U.S. commercial team now launch ready ˗ Marketing … [Read more…]

Company Remains on Track for FDA Submissions of the HeartBeam AIMI™ Software Platform for the Emergency Department in Q3 2022 & AIMIGo™, the Telehealth Solution, in Q4 2022 Acquires Source Code Access Under the LivMor Partnership Agreement that will be Used to Build a Company-branded Version of the LIVMOR’s Halo+ FDA Cleared Turnkey Solution for … [Read more…]